Longeveron (LGVN) Capital Expenditures (2020 - 2025)
Longeveron's (LGVN) quarterly Capital Expenditures came in at $57000.0 in Q3 2025, down 86.74% year-on-year from $430000.0 in Q3 2024, and down 64.6% quarter-over-quarter from $161000.0 in Q2 2025.
Longeveron (LGVN) Capital Expenditures (2020 - 2025) Analysis & Trends
Longeveron's Capital Expenditures history runs 6 years deep, the most recent figure standing at $57000.0 for Q3 2025.
- On a quarterly basis, Capital Expenditures fell 86.74% year-over-year to $57000.0 in Q3 2025; TTM through Mar 2026 was $218000.0, a 67.27% decrease from a year earlier, with the FY2025 full-year figure at $245000.0, down 62.6% from the prior year.
- Capital Expenditures slipped to $57000.0 in Q3 2025 per LGVN's latest filing, from $161000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $430000.0 in Q3 2024 and bottomed at $3000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $72000.0 (2022), against an average of $130125.0.
- Across the five-year window, Capital Expenditures sank 99.21% in 2023 and soared 14233.33% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $312000.0 in 2021, then slumped by 78.85% to $66000.0 in 2022, then jumped by 148.48% to $164000.0 in 2023, then plunged by 92.07% to $13000.0 in 2024, then jumped by 338.46% to $57000.0 in 2025.
- Per Business Quant, the three latest LGVN Capital Expenditures figures stand at $57000.0 (Q3 2025), $161000.0 (Q2 2025), and $27000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Sep 30, 2024 | 430,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 92,000.00 |